Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma ( The BiovaxID Phase 3 clinical trialis ...)

HOME >> MEDICINE >> TECHNOLOGY

Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

The BiovaxID Phase 3 clinical trial is being conducted at fourteen U.S. oncology centers and 8 centers in Russia.

Applications for accelerated conditional approval of BiovaxID are planned to be submitted to both the Food and Drug Administration (FDA) and European Medicines Agency (EMEA) by mid-2008. The DMC has agreed to serve as a liaison between the Company and the FDA and the EMEA. If conditionally approved, BiovaxID could become commercially available in early 2009.

Members of the investment community, the media, and other interested parties can access the PowerPoint presentation and an audio webcast by visiting Accentia's homepage at www.accentia.net, or for audio only, http://www.wsw.com/webcast/jeff18/abpi. The PowerPoint presentation and audio will be available and archived on Accentia's website for 90 days.

About Biovest International, Inc.

Biovest International, Inc., is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., (NASDAQ:ABPI) with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID(TM), which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest is currently conducting a pivotal Phase 3 clinical trial for BiovaxID which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA. For further information, visit the Company Web site at www.biovest.com.

About Accentia Biopharmaceuticals, Inc.

Accentia Biopharmaceuticals, Inc. and its subsidiaries (collectively referred to as the "Company"
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action

Post Your Comments:

(Date:5/22/2013)... Jersey , 22. Mai 2013 /PRNewswire/ ... Fähigkeitsentwicklung und Beratung, gab heute bekannt, dass ... Chris Geraghty , zum Hauptgeschäftsführer ernannt ... Jahre im Industriebereich wo er zahlreiche Führungspositionen ... von Ray Baxter an, der als Kepner-Tregoe ...

(Date:5/22/2013)... 2013 Z-Medica, a leading developer and marketer ... first-ever line of products designed to meet the unique ... ® EMS 4x4 Dressing, QuikClot ® EMS ... Gauze™, all custom-designed to help responders stop bleeding fast ... to a hospital or trauma center. The line includes ...

(Date:5/22/2013)... -- MGT Capital Investments, Inc. (NYSE MKT: MGT) announced today ... Marcum LLP MicroCap Conference on Thursday, May 30, 2013 ... the Grand Hyatt Hotel. Robert Ladd ... and answer questions. (Logo: http://photos.prnewswire.com/prnh/20130409/NY91046LOGO ... begin at 9:30 a.m. EDT. MGT,s latest presentation materials ...

Breaking Medicine Technology:Kepner-Tregoe, Inc. befördert Chris Geraghty zum Hauptgeschäftsführer 2 Kepner-Tregoe, Inc. befördert Chris Geraghty zum Hauptgeschäftsführer 3 Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services 2 MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2 MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 3 MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 4

[0] Kepner-Tregoe, Inc. befördert Chris Geraghty zum Hauptgeschäftsführer [0] Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services [0] MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference

... University of Bari, Italy, concluded that treating patients after ... (SVR) and protects them from liver-related deaths. The purpose ... outcomes of patients posttransplant who underwent antiviral therapy for ... graft. The use in clinical practice ...

... SPRING, Md., Oct. 29 The U.S. Food ... an injectable antibiotic to treat adults with community ... and skin structure infections (ABSSSI), including methicillin-resistant ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ...

Cached Medicine Technology:Achieving Sustained Viral Response for Patients with Recurrent Hepatitis C After Transplantation is Key for Long-Term Outcomes 2 FDA Approves Teflaro for Bacterial Infections 2 FDA Approves Teflaro for Bacterial Infections 3

Achieving Sustained Viral Response for Patients with Recurrent Hepatitis C After Transplantation is Key for Long-Term Outcomes FDA Approves Teflaro for Bacterial Infections

(Date:5/22/2013)... (PRWEB) May 22, 2013 On May 16, ... or more on average, a funeral concierge can help families ... other benefits. Funeral Financials announces their top ... household income in the U.S. having dropped 7.3 ... Sentier Research, the average funeral costs 12.6% of an average ...

(Date:5/22/2013)... (PRWEB) May 22, 2013 TWITTER: @the_USO ... Family Tour together, heading to 8 countries in the next 6 ... Street, Cookie Monster and Members of Congress came together to show ... assembled 2,000 USO Care Packages for distribution to our ... celebrate the five-year partnership of Sesame Street and the USO as ...

(Date:5/22/2013)... Zensah® Compression Apparel released a statement ... titled "Breast pain while running affects one-third of ... help." According to the article, a British study surveyed ... suffer from breast pain while running but do not ... , Zensah emphasizes the importance for women to ...

(Date:5/22/2013)... May 22, 2013 Successful Therapy ... Patricia O’Laughlin Psychotherapy in the Silver Lake community ... all ages as progression to existing Parents and ... ages into parenting therapy has always been suggested, ... O’Laughlin Psychotherapy now specializes in all aspects of ...

(Date:5/22/2013)... (PRWEB) May 22, 2013 Twenty student-led ... next year participating in an intensive startup accelerator designed ... products or services and create local jobs as part ... Each year the Edson initiative offers approximately 20 student ... space, mentorship and training to launch their for-profit, more-than-profit ...

[0] Funeral Financials Announces Their Top 3 Reasons to Hire a Funeral Concierge [0] The USO and Sesame Street Announce Spring Kick Off of World Tour at Biannual Care Package Service Project Event in DC [0] Zensah® Comments on New York Daily News Article Examining How Better Sports Bra Could Help Women Marathoners [0] Patricia O’Laughlin Psychotherapy of Los Angeles Now Seeing Adults, Teens and Young Children [0] ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort

... the same way it responds to winning money and eating ... brain,s reward circuitry. , "We may be ... Matthew D. Lieberman, UCLA associate professor of psychology and a ... a fair offer activates the same brain circuitry as when ...

... April 21 Committed to the safety and,well-being of ... evaluate the recent concerns of the New Jersey Department ... closing of three playing,fields over suspected high lead levels., ... Davis Lee (Ph.D.,Synthetic Organic Chemistry) assert that there is ...

... rate was lower than with malignancies diagnosed on face, ears, ... most deadly melanoma skin cancers occur on the scalp and ... (UNC) study. , Researchers analyzed 51,704 melanoma cases in the ... melanomas died at 1.84 times the rate of patients with ...

... April 21 Versus,Technology, Inc., (Versus) announces ... Kidney Institute that will combine Versus,Real-time Location ... Glickman Urological & Kidney Institute,s clinical,workflow expertise ... The collaboration will develop and document ...

... costs and ... improve productivity, CHICAGO, April 21 ... annually(1), the amount,these families spend on employer-sponsored health care per year ... and,Talent Survey revealed that the median annual contribution for family,healthcare coverage ...

... for Health(R) Dental Health Center Highlights the Importance of Oral ... ... April 21 National dental insurer,United Concordia today unveiled the ... http://www.unitedconcordia.com, empowering,consumers to take charge of their oral ...

Cached Medicine News:Health News:Brain reacts to fairness as it does to money and chocolate 2 Health News:Experts Agree There is No Scientific Evidence of Health Risks in New Jersey Synthetic Turf Fields 2 Health News:Experts Agree There is No Scientific Evidence of Health Risks in New Jersey Synthetic Turf Fields 3 Health News:Melanomas on Scalp and Neck More Deadly 2 Health News:Versus Technology, Inc. Announces Collaboration with Cleveland Clinic to Create Clinical Patient Flow Model 2 Health News:Family Healthcare Contributions Edge Closer to Full Month's Salary, Says Aon Consulting 2 Health News:Family Healthcare Contributions Edge Closer to Full Month's Salary, Says Aon Consulting 3 Health News:Family Healthcare Contributions Edge Closer to Full Month's Salary, Says Aon Consulting 4 Health News:Family Healthcare Contributions Edge Closer to Full Month's Salary, Says Aon Consulting 5 Health News:United Concordia Launches New Online Dental Health Center 2

Brain reacts to fairness as it does to money and chocolate Experts Agree There is No Scientific Evidence of Health Risks in New Jersey Synthetic Turf Fields Melanomas on Scalp and Neck More Deadly Versus Technology, Inc. Announces Collaboration with Cleveland Clinic to Create Clinical Patient Flow Model Family Healthcare Contributions Edge Closer to Full Month's Salary, Says Aon Consulting United Concordia Launches New Online Dental Health Center

Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....

Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....

Used to introduce balloon, electrode, closed or non-tapered end and other catheters....

Sheath Introducer featuring patented SLIX Valve, rotating collar, kink-resistant cannula and atraumatic tip transitions....

Medicine Products:

FLEXOR CHECK-FLO Introducer Set Large Valve Assembly with Radiopaque Band CHECK-FLO Performer Introducers CHILDRENS HOSPITAL BOSTON MODIFICATION CHECK-FLO PERFORMER INTRODUCER SETS Avanti+ Catheter Sheath Introducer